Content tagged as

Drug Development

News
A growing body of evidence suggests that a single dose of vaccine against cancer-causing human papilloma virus (HPV) may protect as well as the standard two-or-more dose regimen. This would make it easier to protect more women, especially in low-income areas where vaccine access is scarce. A study published recently in The Lancet Global Health…
News
A research collaboration has made early progress toward a potential vaccine for type 1 diabetes, a long-sought goal for an autoimmune disease that affects more than 1.5 million Americans. The team, including Frederick National Laboratory computational scientist David Bell, previously discovered a new protein antibody in type 1 diabetes…
News
A research group including Frederick National Laboratory scientists has taken an early step toward a universal influenza vaccine that appears to protect against many strains, including the closely watched H5N1 bird flu. Human trials are under way. Conventional seasonal flu vaccines target the rapidly mutating head of the hemagglutinin (HA)…
News
Maryland scientists came together earlier this month to discuss next-generation vaccine formulation and delivery, as the Biotech Connector speaker series returned to Frederick. The Biotech Connector is a quarterly networking and speaker series, hosted by the Frederick National Laboratory for Cancer Research and Frederick County Chamber of…
News
Scientists at Frederick National Laboratory for Cancer Research and the National Cancer Institute have analyzed nearly two decades’ worth of data about biomedical nanotechnology studies, revealing patterns never seen before. While that may seem exclusively like the domain of laboratory coats and computers, removed from the realm of public…
News
Commercial development of a vaccine against three types of mosquito-borne equine encephalitis viruses — which are classified as potential biological warfare agents and can be fatal in humans — has begun following a government-led phase I clinical trial conducted with materials produced by the Frederick National Laboratory’s Vaccine Clinical…
News
The Biopharmaceutical Development Program (BDP) at Frederick National Laboratory is engineering cells into cancer-killers that are being used to treat children and young adults participating in early-phase pediatric cancer trials. The treatment is called chimeric antigen receptor (CAR) T cell therapy. CAR T cells are a type of white blood cell…
News
Five new projects led by Frederick National Laboratory for Cancer Research (FNL) scientists have earned Laboratory Directed Exploratory Research (LDER) funding for the upcoming fiscal year. The LDER program, which was modeled after the U.S. Department of Energy’s Laboratory Directed Research and Development program, provides FNL scientists…
News
The success of today’s COVID-19 vaccines has given medical nanotechnology a long-awaited boost, with a renewed interest in its potential for treating disease among big pharma and small start-ups. Over the years, nanotechnology has had its ups and downs in the public eye, cycling from peaks of excitement and fanfare–and a little too much hype–…
News
When nanoparticle-based mRNA COVID-19 vaccines were made available in December 2020 and the media began to report the incidence of rare but troubling anaphylaxis, nanomedicine experts including Frederick National Laboratory’s Marina Dobrovolskaia recognized those hypersensitivity reactions. “Everything they reported symptomatically sounded so…